International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours
Latest Information Update: 16 Jan 2026
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms SALUS
- Sponsors Advanced Accelerator Applications
Most Recent Events
- 23 Dec 2025 Planned End Date changed from 30 Jun 2028 to 30 Sep 2027.
- 23 Dec 2025 Planned primary completion date changed from 30 Jun 2028 to 30 Sep 2027.
- 07 Mar 2023 Status changed from recruiting to active, no longer recruiting.